ABBVIE

🇫🇷France
Ownership
-
Established
2013-01-01
Employees
-
Market Cap
$346B
Website
http://www.abbvie.com
Clinical Trials
Related News

Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: ABT-308
Drug: Placebo
First Posted Date
2009-09-29
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
47
Registration Number
NCT00986037

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Phase 1
Completed
Conditions
Lymphoid Malignancy
Solid Tumors
Interventions
Drug: ABT-263
First Posted Date
2009-09-23
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
37
Registration Number
NCT00982566

Efficacy and Safety Study of Elagolix in Women With Endometriosis

Phase 2
Completed
Conditions
Endometriosis, Pain
Interventions
Drug: Placebo
Drug: Elagolix
First Posted Date
2009-09-09
Last Posted Date
2018-09-26
Lead Sponsor
AbbVie
Target Recruit Count
137
Registration Number
NCT00973973

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: ABT-263
Drug: paclitaxel
First Posted Date
2009-05-01
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
19
Registration Number
NCT00891605

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: ABT-288
Drug: Placebo
First Posted Date
2009-04-28
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
81
Registration Number
NCT00888693

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: ABT-263
Drug: gemcitabine
First Posted Date
2009-04-24
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
46
Registration Number
NCT00887757

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

First Posted Date
2009-02-24
Last Posted Date
2017-11-20
Lead Sponsor
AbbVie
Target Recruit Count
87
Registration Number
NCT00850044
Locations
🇺🇸

Site Reference ID/Investigator# 15981, Waukegan, Illinois, United States

Chronic Plaque Psoriasis (Ps) Registry

Completed
Conditions
Chronic Plaque Psoriasis
First Posted Date
2008-12-01
Last Posted Date
2024-03-15
Lead Sponsor
AbbVie
Target Recruit Count
6065
Registration Number
NCT00799877
Locations
🇺🇸

MidSouth Dermatology /ID# 17128, Bartlett, Tennessee, United States

🇺🇸

Northwestern University Feinberg School of Medicine /ID# 28169, Chicago, Illinois, United States

🇺🇸

Brigham Dermatology Associates /ID# 28207, Boston, Massachusetts, United States

and more 336 locations

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

First Posted Date
2008-11-25
Last Posted Date
2018-09-10
Lead Sponsor
AbbVie
Target Recruit Count
174
Registration Number
NCT00797225

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

First Posted Date
2008-11-11
Last Posted Date
2024-06-12
Lead Sponsor
AbbVie
Target Recruit Count
29
Registration Number
NCT00788684
Locations
🇺🇸

Univ of Wisconsin Hosp/Clinics /ID# 21701, Madison, Wisconsin, United States

🇦🇺

Peter MacCallum Cancer Ctr /ID# 25067, Melbourne, Victoria, Australia

🇺🇸

Stanford University School of Med /ID# 9782, Stanford, California, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy